These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 34863919)

  • 1. Association of HLA-B∗35 and moderate or severe cutaneous reactions secondary to benznidazole treatment in chronic chagas disease.
    Bosch-Nicolau P; Salvador F; Sánchez-Montalvá A; Franco-Jarava C; Arrese-Muñoz I; Sulleiro E; Roure S; Valerio L; Oliveira-Souto I; Serre-Delcor N; Pou D; Treviño B; Aznar ML; Espinosa-Pereiro J; Molina I
    Clin Microbiol Infect; 2022 Jun; 28(6):881.e1-881.e5. PubMed ID: 34863919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease.
    Salvador F; Sánchez-Montalvá A; Martínez-Gallo M; Sala-Cunill A; Viñas L; García-Prat M; Aparicio G; Sao Avilés A; Artaza MÁ; Ferrer B; Molina I
    Clin Infect Dis; 2015 Dec; 61(11):1688-94. PubMed ID: 26265500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.
    Torrico F; Gascon J; Ortiz L; Alonso-Vega C; Pinazo MJ; Schijman A; Almeida IC; Alves F; Strub-Wourgaft N; Ribeiro I;
    Lancet Infect Dis; 2018 Apr; 18(4):419-430. PubMed ID: 29352704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres.
    Crespillo-Andújar C; López-Vélez R; Trigo E; Norman F; Díaz-Menéndez M; Monge-Maillo B; Arsuaga M; Pérez-Molina JA
    Clin Microbiol Infect; 2020 Mar; 26(3):384.e1-384.e4. PubMed ID: 31740423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment.
    Pérez-Molina JA; Sojo-Dorado J; Norman F; Monge-Maillo B; Díaz-Menéndez M; Albajar-Viñas P; López-Vélez R
    Acta Trop; 2013 Aug; 127(2):101-4. PubMed ID: 23583863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity of nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: when available options fail.
    Crespillo-Andújar C; Chamorro-Tojeiro S; Norman F; Monge-Maillo B; López-Vélez R; Pérez-Molina JA
    Clin Microbiol Infect; 2018 Dec; 24(12):1344.e1-1344.e4. PubMed ID: 29906591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease.
    Sperandio da Silva GM; Mediano MFF; Hasslocher-Moreno AM; Holanda MT; Silvestre de Sousa A; Sangenis LHC; Brasil PEAAD; Mejía RA; Fux CP; Cubides JC; Saraiva RM; Brum-Soares LM
    J Antimicrob Chemother; 2017 Sep; 72(9):2596-2601. PubMed ID: 28645201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adverse reactions in Chagas disease patients treated with benznidazole, in the State of Ceará].
    de Pontes VM; Souza Júnior AS; Cruz FM; Coelho HL; Dias AT; Coêlho IC; Oliveira Mde F
    Rev Soc Bras Med Trop; 2010; 43(2):182-7. PubMed ID: 20464150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two cases of overlap severe cutaneous adverse reactions to benznidazole treatment for asymptomatic Chagas disease in a nonendemic country.
    González-Ramos J; Noguera-Morel L; Tong HY; Ramírez E; Ruiz-Bravo E; Bellón T; Cabañas R; Cachafeiro L; Herranz-Pinto P
    Br J Dermatol; 2016 Sep; 175(3):604-7. PubMed ID: 26851874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
    Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
    N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.
    Ng CY; Yeh YT; Wang CW; Hung SI; Yang CH; Chang YC; Chang WC; Lin YJ; Chang CJ; Su SC; Fan WL; Chen DY; Wu YJ; Tian YC; Hui RC; Chung WH;
    J Invest Dermatol; 2016 Jul; 136(7):1373-1381. PubMed ID: 26996548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of steroids to prevent cutaneous reactions to benznidazole in patients with Chagas disease.
    Górgolas M; Robles I; Cabello A; Pérez-Tanoira R; Peremarch CP; Fernández-Roblas R; Williams F; Rincón JM
    Pathog Glob Health; 2013 Apr; 107(3):157-60. PubMed ID: 23683371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of benznidazole use in the treatment of chronic Chagas' disease.
    Hasslocher-Moreno AM; do Brasil PE; de Sousa AS; Xavier SS; Chambela MC; Sperandio da Silva GM
    J Antimicrob Chemother; 2012 May; 67(5):1261-6. PubMed ID: 22331592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease.
    Pinazo MJ; Guerrero L; Posada E; Rodríguez E; Soy D; Gascon J
    Antimicrob Agents Chemother; 2013 Jan; 57(1):390-5. PubMed ID: 23114763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment.
    Aldasoro E; Posada E; Requena-Méndez A; Calvo-Cano A; Serret N; Casellas A; Sanz S; Soy D; Pinazo MJ; Gascon J
    J Antimicrob Chemother; 2018 Apr; 73(4):1060-1067. PubMed ID: 29351667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxic Profile of Benznidazole in Patients with Chronic Chagas Disease: Risk Factors and Comparison of the Product from Two Different Manufacturers.
    Molina I; Salvador F; Sánchez-Montalvá A; Treviño B; Serre N; Sao Avilés A; Almirante B
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6125-31. PubMed ID: 26195525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous drug reactions to antiepileptic drugs and relation with HLA alleles in the Turkish population.
    Büyüköztürk S; Kekik Ç; Gökyiğit AZ; Tezer Filik FI; Karakaya G; Saygi S; Dursun AB; Kirbaş S; Tüfekçi A; Sin AZ; Aydoğdu I; Sorgun MH; Aydin N; Gelincik A; Çolakoğlu B; Çelik G; Oğuz F
    Eur Ann Allergy Clin Immunol; 2018 Jan; 50(1):36-41. PubMed ID: 29350020
    [No Abstract]   [Full Text] [Related]  

  • 18. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
    Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
    J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe immune thrombocytopaenia in a patient taking benznidazole for chronic Chagas disease.
    Crespillo-Andújar C; Calbacho Robles M; Norman FF; Pérez-Molina JA
    BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29588298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the HLA-B
    Park HW; Kim DK; Kim SH; Kim S; Chae DW; Yang MS; Oh YK; Lee JP; Jung JW; Shin J; Hwang JH; Kang MG; Kim SM; Kwon SK; Kim HY; Kim MH; Kim SJ; Ryu DR; Cho YJ; Jee YK; Kim SM; Lee EK; Kim JY; Cho HS; Jeong YY; Kim SH; Jun JB; Park JS; Kim GH; Kim S; Jung HY; Lee JM
    J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1271-1276. PubMed ID: 30580048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.